What Visanne Treats

Visanne is a hormonal medication primarily used for the treatment of endometriosis. Endometriosis is a condition where tissue similar to the lining of the uterus grows outside the uterine cavity, often leading to chronic pain and inflammation.

Main Uses

The medication is prescribed to manage the symptoms associated with endometriosis. It contains the progestogen dienogest, which acts by reducing the endogenous production of estradiol. By suppressing the effects of estrogen on the misplaced endometrial tissue, the medication helps to limit the growth and activity of these lesions.

Benefits and Effects

• Reduction of Pelvic Pain: The primary benefit is the significant reduction of endometriosis-associated pelvic pain, including painful menstrual periods, pain during intercourse, and general chronic pelvic discomfort.
• Thinning of the Endometrial Lining: The active ingredient leads to the shrinking of endometrial lesions and a reduction in the inflammatory environment within the pelvis.
• Management of Disease Progression: By creating a hypoestrogenic and hyperprogestogenic environment, the medication helps stabilize the condition and prevent the further proliferation of ectopic tissue.

Mechanism of Action

Unlike some other treatments that completely suppress the cycle to menopausal levels, this medication maintains a specific hormonal balance that is sufficient to treat the lesions while aiming to minimize the impact on bone density and other estrogen-dependent functions. It works through a moderate suppression of the hormones that normally stimulate the growth of the uterine lining each month.

Regulatory References

1. French National Agency for the Safety of Medicines and Health Products

The use of Visanne (dienogest) is strictly limited to women of reproductive age for managing pelvic pain associated with endometriosis. Before starting treatment, pregnancy must be ruled out, and any hormonal contraception must be stopped, with patients advised to use non-hormonal barrier methods instead.

Contraindicated Populations

Use is prohibited (contraindicated) for individuals with the following conditions, which are derived from regulatory documents:

• Vascular/Circulatory Issues: Active or history of venous thromboembolic disorders (e.g., deep vein thrombosis, pulmonary embolism) or arterial and cardiovascular diseases (e.g., myocardial infarction, stroke, ischemic heart disease).
• Diabetes: Diabetes mellitus with vascular involvement.
• Hepatic Impairment: Current or history of severe liver disease (until liver function values have returned to normal) or liver tumours (benign or malignant).
• Malignancy: Known or suspected sex hormone-dependent malignancies (e.g., certain breast cancers).
• Reproductive Status: Known or suspected pregnancy or lactation/breastfeeding.
• Other: Undiagnosed abnormal vaginal bleeding, or hypersensitivity to the active substance or excipients.

Special Consideration Groups

• Adolescents (12 to <18 years): Use is associated with a decrease in bone mineral density (BMD) and requires a careful risk-benefit assessment, particularly with long-term use. The drug is not indicated prior to menarche.
• Other States: Patients with a history of depression, sustained clinically significant hypertension, or a history of extrauterine pregnancy require careful observation or a specific risk-benefit analysis before treatment is initiated or continued.

Visanne's active ingredient, dienogest, is metabolized primarily by the cytochrome P450 3A4 ( CYP3 A4) enzyme system in the liver and intestinal lining. This metabolic pathway is the main focus of clinically relevant drug interactions.

Substances that Reduce Visanne’s Effect (Enzyme Inducers)

Medicines or herbal products that induce or increase the activity of CYP3 A4 can accelerate the clearance of dienogest from the body. This may lead to reduced therapeutic efficacy and potentially result in unwanted changes to the uterine bleeding profile. Specific examples of these enzyme-inducing substances listed in official documents include certain antiepileptics (such as phenytoin, carbamazepine, and primidone), the antibiotic rifampicin, and the herbal remedy St. John's wort (Hypericum perforatum).

Substances that Increase Visanne’s Effect (Enzyme Inhibitors)

Conversely, medicines that inhibit or decrease the activity of the CYP3 A4 enzyme may slow down the metabolism of dienogest, potentially increasing its plasma concentrations. Examples of potent inhibitors include certain antifungals (like ketoconazole and itraconazole), some antibiotics (like erythromycin and clarithromycin), and some antihypertensives (like diltiazem and verapamil).

Other Interactions

Combinations of HIV/Hepatitis C protease inhibitors and non-nucleoside reverse transcriptase inhibitors may either increase or decrease dienogest plasma concentrations, creating a variable and potentially clinically relevant effect. Consultation of the prescribing information for all co-administered medications is necessary to identify potential interactions.

Modulation of the HPO Axis and Local Progesterone Receptor Agonism

Dienogest is a selective Progesterone Receptor (PR) agonist with both central and peripheral actions. Centrally, it activates PRs to exert negative feedback, mediating a controlled reduction of systemic estradiol (E2) output via Hypothalamic-Pituitary-Ovarian (HPO) axis suppression, resulting in a state of moderate systemic hypoestrogenism. Peripherally, this same PR agonism directly triggers cellular differentiation known as decidualization, which is immediately followed by structural atrophy (thinning) of hormone-sensitive cells.

---

Local Anti-Proliferative and Anti-Angiogenic Mechanisms

The mechanism incorporates direct local tissue modulation through enzyme inhibition. Dienogest acts as an inhibitor of Aromatase, reducing the localized estrogen concentration available to the cells. Furthermore, it suppresses factors like Vascular Endothelial Growth Factor (VEGF), which results in an anti-angiogenic effect that restricts local blood vessel growth. The coordination of these local actions is essential for the resultant tissue atrophy and volume reduction.

---

Consequential Anti-Androgenic Action

Structurally, Dienogest also acts as an antagonist at the Androgen Receptor (AR), a secondary effect resulting from AR antagonism. The resultant HPO axis suppression is incomplete, sustaining estradiol (E2) levels higher than those achieved by mechanisms that induce near-total gonadotropin secretion blockade. The physical volume reduction and concurrent loss of tissue vitality are direct consequences of the local molecular mechanism.

Visanne is an oral preparation with a fixed daily dose for the continuous management of its approved indication. Its administration is designed to ensure consistent use without interruption. The medicine is supplied as a film-coated tablet containing 2 mg of dienogest intended for the oral route of administration. The standard adult regimen is one tablet daily, which constitutes the standard maximum dose for the approved use.

---

Official Administration Guidelines

Administration Feature	Official Instruction
Dosing Schedule	One 2 mg tablet once daily.
Continuity of Use	Intake is continuous; there should be no break between packs, and administration proceeds without regard to the menstrual cycle.
Timing of Intake	The tablet should be taken preferably at the same time each day. It may be taken with or without food.

---

Procedural Rules for Use

Administration can be initiated on any day of the menstrual cycle. In the event of a missed tablet, the instruction is to take one tablet only as soon as it is remembered, and then continue the next day at the usual scheduled time, ensuring no two doses are taken on the same day.

A procedural constraint is that all hormonal contraceptive methods must cease before beginning Visanne therapy. If contraception is required during treatment, a non-hormonal method must be employed. Use is restricted to women post-menarche and is not indicated for the geriatric population, consistent with the official product labeling.

Research Evidence / Overview of Studies for Visanne

This summary provides an overview of the research that has examined the compound Dienogest (the active ingredient in Visanne) in the context of endometriosis. It describes the types of studies conducted and what their findings suggest, without offering clinical advice or making personal predictions.

---

Evidence from Trials for Endometriosis-Associated Pelvic Pain

The foundation of the evidence for the use of Visanne was studied in research exploring symptoms such as endometriosis-associated pelvic pain (EAPP) and dysmenorrhoea (painful periods), and comes from Randomized Controlled Trials (RCTs). These studies contribute to the broader evidence landscape as they often compare the investigational treatment against a placebo (an inactive substance) over a defined period.

Researchers monitored several patient-reported outcomes describing perceived discomfort in adult women, including measurements of overall pain intensity using standardized scales. The main trials typically spanned short-term to intermediate-term follow-up durations, ranging from a few months up to about 15 months. Evidence is broadly considered to have reached a High level of consolidation through multiple placebo-controlled trial structures.

---

Research on Managing Endometriosis Lesions and Post-Surgical Recurrence

Research has also explored the use of Dienogest in contexts beyond the short-term outcomes related to physical discomfort, focusing on long-term recurrence patterns.

Endometrioma Size and Characteristics in Studies

Certain studies examined the effect on lesions or endometriomas (cysts that form on the ovaries). Researchers used imaging techniques to monitor the size or volume of the endometriomas over time. This outcome was observed in some studies, although it was usually a secondary outcome. Findings describe patterns related to size monitoring in the observed populations. The research supporting this is broadly considered Moderate in evidence level.

Post-Surgical Recurrence Patterns

Other research, primarily consisting of observational cohort studies and Systematic Reviews, monitored outcomes such as the rate of symptom recurrence (when pain returned) and the time elapsed until the recurrence of symptoms after conservative surgery. This evidence contributes to the broader evidence landscape by providing insight into longer observation periods.

---

Evidence Gaps and Areas of Research Uncertainty

It is important to understand the areas where the research remains insufficient or incomplete:

• Follow-up durations were limited in the initial, highest-quality controlled trials, meaning long-term outcomes are less well-characterized.
• Data for certain groups remain insufficient, especially for women with certain severe subtypes of the condition or women with specific co-existing health conditions.
• Findings describe group patterns, not personal outcomes. Study results reflect the specific conditions under which they were conducted and research does not determine whether an individual will respond similarly.

Key Studies & References

1. Dienogest as a Maintenance Treatment for Endometriosis Following Surgery: A Systematic Review and Meta-Analysis
2. Visanne Study to Assess Safety in Adolescents (VISADO): A Multi-center, Open Label, Single-arm Study to Investigate the Safety and Efficacy of Daily Oral Administration of 2 mg Dienogest Tablets for the Treatment of Endometriosis in Adolescents
3. Visanne 2 mg tablets - Summary of Product Characteristics (SPC) - European Regulatory Information (Includes BMD details for adolescents and general evidence summary)

Common questions about Visanne (FAQ)

Q: What is the active substance in Visanne?

A: According to the official product information, the active substance in Visanne is dienogest. Dienogest is classified as a progestogen, which is a type of hormone used to manage the condition.

Q: What is Visanne used to treat?

A: Regulatory documents state that Visanne is indicated for the treatment of endometriosis. Endometriosis is a common condition where tissue similar to the lining of the womb (endometrium) grows outside the uterus.

Q: Does Visanne cure endometriosis?

A: Official information indicates that Visanne is a treatment designed to reduce the painful symptoms associated with endometriosis. It is not described in regulatory documents as a permanent cure for the disease.

Q: How does Visanne work to treat endometriosis?

A: Visanne works by suppressing the production of the hormone oestradiol, which stimulates the growth of endometrial tissue. The active substance, dienogest, helps to reduce the hormone-dependent lesions of endometriosis, potentially leading to symptom relief.

Q: Can Visanne be used as a contraceptive (birth control)?

A: Official product information specifies that Visanne is not a contraceptive. While the medication may affect the menstrual cycle, it should not be relied upon to prevent pregnancy. The use of non-hormonal contraception methods is generally advised while taking this medication.

Q: Is it normal to have changes in bleeding while taking Visanne?

A: Studies and official information indicate that changes in the bleeding pattern are very common when taking Visanne. This can include spotting, infrequent bleeding, or a complete absence of bleeding (amenorrhea). The bleeding pattern often evolves as treatment continues.

Q: Can Visanne affect bone density?

A: Regulatory documents state that there may be a change in bone mineral density in some patients taking Visanne, particularly in adolescents. Decisions regarding bone density risk, especially for adolescents or those with existing risk factors, are typically made by a healthcare provider.

Q: What happens if I forget to take a tablet?

A: The official product information mentions that if a tablet is missed, the contraceptive effect is no longer assured, which supports the need for non-hormonal contraception. Specific instructions regarding a missed dose are detailed in the official patient information leaflet.

Q: Is it possible to become pregnant while taking Visanne?

A: According to the official product information, Visanne is not considered a reliable contraceptive. Therefore, the potential for pregnancy exists, and the use of non-hormonal contraception is advised during treatment.

Storage and Stability

Visanne (dienogest) tablets must be stored according to specific regulatory guidelines to maintain their stability and effectiveness. The medication should be kept at room temperature, generally defined as below 30 C or between 15 C and 30 C, depending on the authority. To protect the tablets from light and moisture, it is required to store them in their original blister pack or container. Do not store the medicine in damp areas such as a bathroom or near a sink. Ensure the product is always kept out of the sight and reach of children and pets.

Disposal Requirements

Do not use Visanne after the expiry date printed on the packaging. Unused or expired medication should not be disposed of via household waste or wastewater (e.g., flushing down the toilet). Official guidelines instruct patients to return any unused medicine to a pharmacist or utilize a recognized medication take-back program for safe disposal.